Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.


HHS - 960 - National Cancer Advisory Board - Statutory (Congress Created)
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameNational Cancer Advisory BoardAgency NameDepartment of Health and Human Services
Fiscal Year2020Committee Number960
Original Establishment Date11/20/1985Committee StatusChartered
Actual Termination Date Committee URLhttp://deainfo.nci.nih.gov/advisory/ncab/ncab.htm
New Committee This FYNoPresidential Appointments*Yes
Terminated This FYNoMax Number of Members*30
Current Charter Date5/31/2020Designated Fed Officer Position Title*DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI
Date Of Renewal Charter5/31/2022Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*PAULETTE
Exempt From Renewal*NoDesignated Federal Officer Middle NameS.
Specific Termination AuthorityDesignated Federal Officer Last Name*GRAY
Establishment Authority*Statutory (Congress Created)Designated Federal Officer SuffixPH.D.
Specific Establishment Authority*42 U.S.C. 284aDesignated Federal Officer Phone*240-276-6340
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*240-276-7815
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*grayp@mail.nih.gov
Committee Type*Continuing
Presidential*No
Committee Function*Other Committee
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The National Cancer Advisory Board (NCAB), composed of both scientific and public members, provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed $50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). In FY 2020, the NCAB reviewed 13,014 NCI applications requesting $4,482,059,843 and 7 FDA SBIR applications requesting $1,078,462. During the year, the NCAB was presented reports on various topics related to cancer research in general. Board discussions and reports included a wide variety of topics including the Comparative Oncology Program: Clinical Trial in Dogs with Cancer and Insight for Humans; Nature as a Remarkable Chemist: The Story of Taxol; Cancer Grand Challenges Collaboration with CRUK; Foreign Influences on Research Integrity; Exceptional Responders Program; Intramural Research Program (IRP) Neurofibromatosis Type 1 (NF1) Program; NCI Activities Related to COVID-19; New York University Langone Health: NYCOVID-19 Reflections from the Epicenter; Clinical Trials Policies; an Update on COVID–19 Serology and Immunology Capacity Building; NCI-Supported Clinical Research During the COVID-19 Pandemic; Minority Accrual to NCI’s National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP) Clinical Trials; Board of Scientific Advisors (BSA) Childhood Cancer Data Initiative (CCDI) ad hoc Working Group Report; The Impact of Advances in Lung Cancer Treatment on Population Mortality; and an Update on the TMIST – Tomosynthesis Mammographic Imaging Screening Trial. NCAB members provided insights regarding reports from the NCAB Ad Hoc Subcommittees on Global Cancer Research; Experimental Therapeutics; and Population Sciences, Epidemiology, and Disparities. They also provided insights regarding reports from the NCAB Subcommittees on Clinical Investigations and Planning and Budget. The Board approved the establishment of an ad hoc Working Group on Clinical Trials Enrollment and Retention that will report to the NCI Council of Research Advocates (NCRA) and an ad hoc Working Group on Cancer Screening Trials that will report to the Clinical Trials and Translational Research Advisory Committee (CTAC). At the Joint Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism, National Advisory Council on Drug Abuse and NCAB met to hear reports regarding the Adolescent Brain and Cognitive Development (ABCD) Study and updates from the NCI, NIAAA, and NIDA regarding efforts associated with the Collaborative Research on Addiction at NIH (CRAN) initiative. Lastly, NCAB meeting minutes for the September 2019 meeting, December 2019 Joint NCI Board of Scientific Advisors/NCAB meeting, as well as the following virtual meetings, i.e., the: NCAB February 2020, NIAAA/NIDA/NCAB May 2020, April 2020 Joint NCI BSA/NCAB, and June 2020 Joint NCI BSA/NCAB were approved by the Board members during fiscal year 2020.
How is membership balanced?*The Board will consist of not more than 18 members appointed by the President (appointed members) and 12 nonvoting ex officio members. The nonvoting ex officio members will include the Secretary; the Director of the Office of Science and Technology Policy; the Director, NIH; the Under Secretary for Health of the Department of Veterans Affairs; the Director of the National Institute for Occupational Safety and Health; the Director of the National Institute of Environmental Health Sciences; the Secretary of Labor; the Commissioner of the Food and Drug Administration; the Administrator of the Environmental Protection Agency; the Chairman of the Consumer Product Safety Commission; the Assistant Secretary of Defense for Health Affairs; and the Director of the Office of Energy Research of the Department of Energy (or their designees). All appointed members must be eligible to serve as Special Government Employees (SGEs) and will serve as SGEs. Two-thirds of the appointed members will be selected from among the leading representatives of the health and scientific disciplines (including not less than 2 individuals who are leaders in the fields of public health and the behavioral or social sciences) relevant to the activities of NCI. One-third of the appointed members will be representatives from the general public, including leaders in fields of public policy, law, health policy, economics and management. Not less than five of the appointed members will be individuals knowledgeable in environmental carcinogenesis (including carcinogenesis involving occupational and dietary factors). Not less than one member shall be an individual knowledgeable in pediatric oncology.
How frequent & relevant are cmte mtgs?*As mandated, meetings are held not less than four times a year. The committee met six times during this reporting period. The Board met jointly with NIAAA/NIDA on 13 May 2020 and jointly with the NCI Board of Scientific Advisors for the December 2019, April 2020, and June 2020 meetings. The Board also met virtually at the February 2020 and September 2020 meetings. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing scientific programs. The Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities and the Clinical Investigations Subcommittee met on 2 December 2019. The Ad Hoc Subcommittees on Population Science, Epidemiology and Disparities; Global Cancer Research; Experimental Therapies; and the Planning and Budget Subcommittee met on 1 September 2020.
Why advice can't be obtained elsewhere?*The NCAB provides second level of peer review and advises on policy development; program implementation, and evaluation; and identifies research needs and opportunities of the Institute. The quality, scope, and balance of advice from this Board cannot be obtained from NIH staff or from other established sources as membership of the Board is constituted to meet specific requirements of the mandated mission of the Board and of the NCI.
Why close or partially close meetings?The meetings of the NCAB were closed to the public for the review of grant applications. Sections 552b(c)(4) and 552b(c)(6) of the Government in the Sunshine Act permit the closing of meetings where discussion of applications could reveal confidential trade secrets or commercial property such as patentable material and personal information, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Recommendation RemarksCommittee Function: Other - National Scientific and Advisory.

Members: The terms of service for Peter Adamson, Deborah Bruner, Yuan Chang, David Christiani, Judy Garber, Elizabeth Jaffee, Beth Karlan, Tim Ley, Mack Roach, Charles Sawyers, and Max Wicha have changed due to administrative extensions. As such, their term of service dates are different than what was reported on the FY19 ACR. Scott Hiebert was reassigned as Acting Chair, as such his membership record was updated indicate his role as Acting Chair. The terms for Elizabeth Jaffee, David Christiani, Judy Garber, Beth Karlan, Mack Roach, and Charles Sawyer are longer than the charter allows due to delays in the appointment of new members and to ensure appropriate expertise was available for the mandatory second level of peer review.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.

Reports: This committee did not produce any public reports.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentNoAction Reallocate ResourcesYes
Outcome Major Policy ChangesYesAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingYesAction Approved Grants Or Other PaymentsYes
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionNoAction CommentAn action of approved or recommended for grants receiving review by this Board does not infer that the grant will be or has been funded. Research grant applications submitted to NIH must go through a two-step review process that includes the initial peer review for scientific and technical merit and a second step of review and approval by the National Advisory Council that includes program relevance. In addition, prior to an award or funding being made, NIH staff must conduct an administrative review for a number of other considerations. These include alignment with NIH's funding principles, review of the project budget, assessment of the applicant's management systems, determination of applicant eligibility, and compliance with public policy requirements. After all these steps, have been completed, NIH officials make funding decisions on individual grant applications. NCI used its resources to support the best science and ensure continued advances with a focus on basic science to drive novel approaches and technologies; workforce development; health disparities; data aggregation and interpretation; and clinical trials. There were also well-reasoned discussions regarding the impact of the pandemic on the overall workforce, NCI supported research, and NCI new activities related to COVID-19, which included clinical research as well as serology and immunology capacity building. NCAB members provided thoughtful advice on several scientific advances presented regarding comparative oncology; the exceptional responders program; neurofibromatosis; minority accrual to NCI’s National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP) Clinical Trials; and advances in lung cancer treatment. Additionally, the Board deliberated and approved the establishment of an ad hoc Working Group on Clinical Trials Enrollment and Retention that will report to the NCI Council of Research Advocates (NCRA) and an ad hoc Working Group on Cancer Screening Trials that will report to the Clinical Trials and Translational Research Advisory Committee (CTAC).
Outcome Implement Laws/Reg RequirementsYesGrants Review*Yes
Outcome OtherYesNumber Of Grants Reviewed13,021
Outcome CommentThe NCAB continues to be instrumental in monitoring the development and execution of the activities of the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. In 2020, NCI used its resources to support the best science and ensure continued advances with a focus on basic science to drive novel approaches and technologies; workforce development; health disparities; data aggregation and interpretation; and clinical trials. There were also well-reasoned discussions regarding the impact of the pandemic and NCI activities related to COVID-19 which included clinical research as well as serology and immunology capacity building. NCAB members provided thoughtful advice on several scientific advances presented regarding comparative oncology; the exceptional responders program; neurofibromatosis; minority accrual to NCI’s National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP) Clinical Trials; and advances in lung cancer treatment. Additionally, the Board deliberated and approved the establishment of an ad hoc Working Group on Clinical Trials Enrollment and Retention that will report to the NCI Council of Research Advocates (NCRA) and an ad hoc Working Group on Cancer Screening Trials that will report to the Clinical Trials and Translational Research Advisory Committee (CTAC).Number Of Grants Recommended13,021
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$4,483,138,305.00
Cost Savings CommentNIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.Grants Review CommentThe number of grants reviewed/recommended and dollar value includes NCI grants and FDA SBIR grants.
Number Of Recommendations*216Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentIn additional to some general recommendations, in FY 2020 some specific committee recommendations include the following: A motion to concur on establishing the Cancer Grand Challenges Initiative, a new NCI program in collaboration with Cancer Research United Kingdom (CRUK), was approved unanimously; A motion to accept the report of the 2 December 2019 NCAB ad hoc Population Science, Epidemiology, and Disparities Subcommittee meeting was approved unanimously; A motion to concur on establishing an NCAB ad hoc Working Group on Cancer Disparities was approved unanimously; A motion to accept the report of the 2 December 2019 NCAB Clinical Investigations Subcommittee meeting was approved unanimously; A motion to approve the NCI Annual Delegations of Authority was approved unanimously; A motion to concur on the NCI Policy on Percent Effort on Grants was approved unanimously; A motion to concur with establishing an NCI Council of Research Advocates ad hoc Working Group on Clinical Trials Enrollment and Retention, with modification to expand the focus and mission statement, was approved unanimously; A motion to concur with establishing an NCI Clinical Trials and Translational Research Advisory Committee ad hoc Working Group on Cancer Screening Trials was approved with 14 ayes, 0 nays, and 1 abstention; A motion to accept the report of the virtual 1 September 2020 NCAB ad hoc Population Science, Epidemiology, and Disparities Subcommittee meeting was approved unanimously; A motion to accept the report of the virtual 1 September 2020 NCAB ad hoc Global Cancer Research Subcommittee meeting was approved unanimously; A motion to accept the report of the virtual 1 September 2020 NCAB Planning and Budget Subcommittee meeting was approved unanimously; A motion to accept the report of the virtual 1 September 2020 NCAB ad hoc Experimental Therapeutics Subcommittee meeting was approved unanimously; and A motion to support the NCI strategy to increase R01 paylines to the 15th percentile was approved unanimously.Access Agency WebsiteYes
% of Recs Fully Implemented*0.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentInformation on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*0.00%Access PublicationsYes
% of Recs Partially Implemented CommentInformation on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access OtherYes
Agency Feedback*YesAccess CommentInformation on the NCAB can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm. Each NCI committee’s charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint Presentations and reports is located here. Additionally, the public may view the NCAB meetings (both live and on demand) via the NIH Videocast at the following website: http://videocast.nih.gov/.
Agency Feedback Comment*NCI Director and Deputy Directors report at each Board Meeting; the President's Cancer Panel Report; NCI Annual Reports; Biennial reports; and a list of Action Items for each meeting are reviewed and assigned to individual NCI staff with specific time frames with deadlines.Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. NCI works to fufill that mission with the support of the National Cancer Advisory Board (NCAB), which is composed of both scientific and public members, and provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed $50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). During the year, the NCAB was presented reports on various topics related to cancer research in general, and the operational aspects of the Institute's intramural and extramural programs. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing research programs.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$41,600.00Est Payments to Non-Fed Members Next FY*$41,600.00
Payments to Federal Members*$3,928.00Est. Payments to Fed Members Next FY*$3,928.00
Payments to Federal Staff*$81,599.00Estimated Payments to Federal Staff*$86,679.00
Payments to Consultants*$1,200.00Est. Payments to Consultants Next FY*$1,200.00
Travel Reimb. For Non-Federal Members*$9,849.00Est Travel Reimb Non-Fed Members nextFY*$9,905.00
Travel Reimb. For Federal Members* Est Travel Reimb For Fed Members* 
Travel Reimb. For Federal Staff* Est. Travel Reimb to Fed Staff Next FY* 
Travel Reimb. For Consultants*$5,683.00Est Travel Reimb to Consultants Next FY*$5,727.00
Other Costs$62,153.00Est. Other Costs Next FY*$62,775.00
Total Costs$206,012.00Est. Total Next FY*$211,814.00
Federal Staff Support (FTE)*0.50Est. Fed Staff Support Next FY*0.60
Cost RemarksDue to the COVID-19 pandemic, FY2020 meetings held after March 12, 2020 were virtual only, which reduced committee operating costs. If face to face meetings resume, committee costs for FY2021 may be higher.

The increase in Federal Staff costs and support were due to staffing changes during the fiscal year. Daily salary costs have been estimated for Ex Officio members of this committee. The dollar figure represents a portion of their annual salary. No funds have been transferred between the committee and the agency. No additional funds are paid to Federal employee. Although 9 Ex officio members are identified in the member section, only 4 attended meetings during the fiscal year.
Est Cost Remarks
Hide Section - Interest Areas

Interest Areas

Category
Area
Environment
Environmental Issues
Health
Health Care
Medicine
Health and Health Research
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-036650National Cancer Advisory Board2019
 COM-034864National Cancer Advisory Board2018
 COM-001697National Cancer Advisory Board2017
 COM-002625National Cancer Advisory Board2016
 COM-004095National Cancer Advisory Board2015
 COM-004406National Cancer Advisory Board2014
 COM-005879National Cancer Advisory Board2013
 COM-006663National Cancer Advisory Board2012
 COM-007989National Cancer Advisory Board2011
 COM-008841National Cancer Advisory Board2010
 COM-010335National Cancer Advisory Board2009
 COM-010812National Cancer Advisory Board2008
 COM-012087National Cancer Advisory Board2007
 COM-012898National Cancer Advisory Board2006
 COM-013966National Cancer Advisory Board2005
 COM-014620National Cancer Advisory Board2004
 COM-015893National Cancer Advisory Board2003
 COM-016493National Cancer Advisory Board2002
 COM-018011National Cancer Advisory Board2001
 COM-018728National Cancer Advisory Board2000
 COM-019867National Cancer Advisory Board1999
 COM-020396National Cancer Advisory Board1998
 COM-021687National Cancer Advisory Board1997